{ "checked": "2026-10-27", "page": "https://jabbitapp.com/research/ozempic-vulva-vagina-pelvic-floor-glp1-wegovy-zepbound-teardown.html", "why_now": "A public X post created October 27, 2026 at 1:44 AM ET asking about Ozempic and the pelvic floor had 293,094 impressions when read at about 5:55 AM ET (post id 2114956421393723815; the poster, a private individual, is not named on the page).", "abstract_quotes": { "19179316": { "title": "Weight loss to treat urinary incontinence in overweight and obese women", "journal": "N Engl J Med", "quotes": [ "We randomly assigned 338 overweight and obese women with at least 10 urinary-incontinence episodes per week to an intensive 6-month weight-loss program that included diet, exercise, and behavior modification (226 patients) or to a structured education program (112 patients).", "The women in the intervention group had a mean weight loss of 8.0% (7.8 kg), as compared with 1.6% (1.5 kg) in the control group (P<0.001).", "After 6 months, the mean weekly number of incontinence episodes decreased by 47% in the intervention group, as compared with 28% in the control group (P=0.01).", "As compared with the control group, the intervention group had a greater decrease in the frequency of stress-incontinence episodes (P=0.02), but not of urge-incontinence episodes (P=0.14)." ] }, "20664387": { "title": "Improving urinary incontinence in overweight and obese women through modest weight loss", "journal": "Obstet Gynecol", "quotes": [ "Weight losses between 5% and 10% of body weight were sufficient for significant urinary incontinence benefits.", "approximately 75% of women who lost 5% to less than 10% of their body weight reported being moderately or very satisfied with their changes in urine leakage." ] }, "22264468": { "title": "Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial", "journal": "J Urol", "quotes": [ "Women in this substudy (2,739, mean ± SD age 57.9 ± 6.8 years, body mass index 36.5 ± 6.1 kg/m(2))", "At 1 year fewer women in the intensive lifestyle intervention group reported urinary incontinence (25.3% vs 28.6% in the diabetes support and education group, p = 0.05).", "Among participants without urinary incontinence at baseline 10.5% of intensive lifestyle intervention and 14.0% of diabetes support and education participants experienced urinary incontinence after 1 year (p = 0.02).", "There were no significant group differences in the resolution of urinary incontinence (p >0.17).", "weight losses of 5% to 10% reduced these odds by 47% (p = 0.002)." ] }, "22453270": { "title": "Prolapse symptoms in overweight and obese women before and after weight loss", "journal": "Female Pelvic Med Reconstr Surg", "quotes": [ "A higher proportion of obese women reported feeling vaginal bulging compared with overweight women (13% vs 0%, P = <0.01).", "At 6 months, there were no significant differences in improvement of self-reported bothersome prolapse symptoms in women in the weight loss or the control group.", "Weight loss did not improve bothersome prolapse symptoms." ] }, "18669733": { "title": "Obesity and pelvic floor disorders: a systematic review", "journal": "Obstet Gynecol", "quotes": [ "Weight loss studies indicate that both bariatric and nonsurgical weight loss lead to significant improvements in pelvic floor disorder symptoms.", "There is little evidence on which to base clinical decisions regarding the treatment of fecal incontinence and POP in obese women" ] }, "42465136": { "title": "Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review", "journal": "Cureus", "quotes": [ "Urinary incontinence and overactive bladder improve or resolve in 50-70% of women after bariatric surgery." ] }, "42748969": { "title": "[GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects]", "journal": "Zentralbl Chir", "quotes": [ "indirect benefit for stress incontinence and overactive bladder via weight loss", "a near-complete absence of data in women" ] }, "41870138": { "title": "GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research", "journal": "Sex Med Rev", "quotes": [ "In humans, evidence remains mixed.", "Pharmacovigilance analyses from the FDA Adverse Event Reporting System revealed reports of erectile dysfunction, decreased libido, and orgasmic dysfunction among GLP-1 RA users, but disproportionality analyses indicated insignificant associations.", "However, recent clinical case reports have identified possible female sexual side effects." ] }, "42517362": { "title": "Weight loss interventions and sexual function in midlife women: the emerging role of glucagon-like peptide-1 receptor agonists", "journal": "Menopause", "quotes": [ "may paradoxically suppress sexual desire and arousal through central neuroendocrine mechanisms", "While emerging case reports and preclinical data support this concern, systematic clinical evidence remains limited", "lifestyle interventions and bariatric surgery have demonstrated meaningful improvements in sexual function." ] }, "40487373": { "title": "Tirzepatide Affect Sexual Function in Women: Case Report", "journal": "Clin Med Insights Case Rep", "quotes": [ "During treatment, the patient started to complain of decreasing sexual drive, genital dryness, and failure to catch orgasm; female sexual function index (FSFI) = 12.7.", "Symptoms decreased after stopping the tirzepetide (FSFI = 28.7) and reappeared after retaking the injection (FSFI = 14.7)." ] }, "40666108": { "title": "Anorgasmia following initiation of GLP-1 agonist", "journal": "Sex Med", "quotes": [ "very little is known regarding sexual dysfunction as a side effect of GLP-1 agonists." ] }, "41716526": { "title": "Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health", "journal": "Urol Case Rep", "quotes": [ "A 40-year-old male developed reproducible urinary frequency, penile pruritus, dysuria, pelvic/perineal pain, and sexual dysfunction 3-4 weeks after initiating tirzepatide therapy." ] } }, "conflict_statements": { "42517362": "Financial disclosures/Conflicts of interest: M.D.H.A. has served as a consultant for Novo Nordisk, Hoffman-La Roche, and Verge Genomics. Dr. Hurtado Andrade receives research funding from the National Institute of Health (K12-AR084222), the Mayo Clinic Center for Women’s Health Research, Eli Lilly, Endogenex, and Phenomix Sciences. C.L.S. is an advisor for Bayer Pharmaceutics. S.S.F. is a consultant for Era Women’s Health Platform, delivers CME lectures for PriMed, AiCME, MedAll, and Medscape, and serves on the scientific advisory board for Weight Watchers. The other authors have nothing to disclose.", "40666108": "None declared.", "40487373": "The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article." }, "jsm_2026_trinetx_abstract": { "doi": "10.1093/jsxmed/qdag063.010", "authors": [ "Hammad MA", "Nakamura HS", "Yih J" ], "quotes": [ "The exposure cohort consisted of women prescribed GLP-1RAs, identified by semaglutide (RxNorm 1 991 382) or other GLP-1 analogues (ATC A10BJ), totaling 618 362 individuals.", "The control group comprised 84 711 992 non-diabetic females with no GLP-1RA exposure.", "162 health-care organizations", "N90.5 (atrophy of vulva), N90.6 (hypertrophy of vulva), N90.68 (unspecified hypertrophy of vulva), and N90.69 (other specified hypertrophy of vulva)", "After exclusion of patients with pre-existing outcomes, 617 407 GLP-1RA users with a mean follow-up of 680 ± 656 days and 84 711 992 non-users were included in the final analysis.", "Vulvar atrophy or hypertrophy was diagnosed in 375 GLP-1RA users (0.061%) and 51 157 non-users (0.060%).", "The absolute risk difference was 0.001% (95% CI –0.02 to 0.02), with a two-tailed p-value of 0.97", "Incidence proportions were calculated and compared between groups using z-tests for two independent proportions", "Further research incorporating imaging, histologic, and patient-reported data is warranted to explore potential subclinical or aesthetic tissue alterations following rapid weight loss.", "Disclosure No." ], "note": "Conference abstract (ISSWSH 2026), not peer-reviewed as a full paper; not indexed in PubMed when checked." }, "contemporary_obgyn_2026_02_23": [ "Is the provider who’s prescribing these medications screening or diagnosing patients with those diagnoses? Or is it really only when those patients have significant concerns that they’re coming forward and being evaluated for that?", "It’s not really something that everybody has to worry about,", "presented findings at the 2026 International Society for the Study of Women’s Sexual Health (ISSWSH) annual meeting", "with the propensity score matching" ], "asps_2026_01_22": [ "Ozempic vulva is a phrase being used, especially on social media, to describe how rapid weight loss affects the female genitalia.", "significant weight loss from GLP-1 medications – or really any form of weight loss – can cause deflation of the soft tissues, resulting in a more baggy labia majora and possibly more protrusion of the labia minora,", "Muscle weakness or loss in the pelvic floor may lead some patients to experience minor urinary incontinence or discomfort.", "Thursday, January 22, 2026" ], "medscape_2026_04_07": [ "The labia minora prominence that can result from fat loss in the labia majora has been dubbed “ Ozempic vulva.”", "Many report constipation, which can lead to straining that increases their risk for urinary incontinence and pelvic organ prolapse.", "“Most of the symptoms I see are not caused directly by the medication itself but rather by the consequences of rapid weight loss that hasn’t been properly supported,” Lowry said.", "That could be partly from the GLP-1, but it could also be GSM symptoms.", "But “it can be helpful to understand how broad normal vulvar appearance can be,” Moss said.", "“who wouldn’t think to ask about vulvar skin or genital concerns or sexual health concerns,”", "The sources declared no financial conflicts of interest.", "April 07, 2026" ], "pubmed_searches": [ { "query_translation": "(\"semaglutide\"[Supplementary Concept] OR \"semaglutide\"[All Fields] OR \"semaglutide\"[MeSH Terms] OR (\"tirzepatide\"[Supplementary Concept] OR \"tirzepatide\"[All Fields] OR \"tirzepatide\"[MeSH Terms]) OR (\"liraglutid\"[All Fields] OR \"liraglutide\"[Supplementary Concept] OR \"liraglutide\"[All Fields] OR \"liraglutide\"[MeSH Terms] OR \"liraglutide s\"[All Fields]) OR \"GLP-1\"[All Fields]) AND (\"pelvic organ prolapse\"[All Fields] OR \"uterine prolapse\"[All Fields] OR \"vaginal prolapse\"[All Fields])", "count": "0" }, { "query_translation": "(\"semaglutide\"[Supplementary Concept] OR \"semaglutide\"[All Fields] OR \"semaglutide\"[MeSH Terms] OR (\"tirzepatide\"[Supplementary Concept] OR \"tirzepatide\"[All Fields] OR \"tirzepatide\"[MeSH Terms]) OR \"GLP-1\"[All Fields]) AND (\"vulva\"[MeSH Terms] OR \"vulva\"[All Fields] OR \"vulvas\"[All Fields] OR \"vulvae\"[All Fields] OR (\"vulva\"[MeSH Terms] OR \"vulva\"[All Fields] OR \"vulvar\"[All Fields]) OR (\"labia\"[All Fields] OR \"labiae\"[All Fields]))", "count": "10" } ], "labels": { "wegovy_dailymed_setid": "ee06186f-2aa3-4990-a760-757579d8f77b", "zepbound_dailymed_setid": "487cd7e7-434c-4925-99fa-aa80b1cc776b", "terms_not_found_in_either": [ "vulv", "vagin", "pelvic", "genital", "labia", "libido", "sexual", "prolapse", "incontinence" ], "zepbound_hair_loss_quote": "Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction.", "zepbound_most_common": "most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease.", "wegovy_most_common": "Most common adverse reactions (incidence ≥5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss." }, "registry": { "nct": "NCT07175805", "title": "Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy", "sponsor": "Hartford HealthCare", "status": "NOT_YET_RECRUITING", "type": "OBSERVATIONAL", "enrollment": 200, "primary_completion": "2026-10", "last_update": "2025-09-16", "primary_outcomes": [ "Change in pelvic floor symptoms measured by survey the Urogenital Distress Inventory (UDI)", "Change in pelvic floor symptoms measured by validated survey the Colorectal-Anal Distress Inventory (CRADI-8)." ] }, "rates_chart": { "trinetx": [ { "group": "GLP-1 users", "percent": 0.061, "n": 375, "denominator": 617407 }, { "group": "Non-users", "percent": 0.06, "n": 51157, "denominator": 84711992 } ], "pride_incontinence_episode_drop_pct": { "weight_loss": 47, "control": 28 }, "look_ahead_new_incontinence_pct": { "lifestyle": 10.5, "control": 14.0 } }, "analysis": { "note": "Jabbit analysis. No study we found links GLP-1 drugs to pelvic organ prolapse; our PubMed search returned no records. Randomized weight-loss trials without drugs (PRIDE, Look AHEAD) found less urinary incontinence and no improvement or worsening in prolapse symptoms. 'Ozempic vulva' describes fat loss in the labia majora and mons, a weight-loss effect described by surgeons and clinicians; one large health-record abstract found no rise in coded vulvar atrophy or hypertrophy, but coded diagnoses miss cosmetic changes. Sexual side effects rest on case reports and reviews." } }